Related Experiment Video
Updated: Jul 2, 2026
11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
Taurine supplementation modulates glucose homeostasis and islet function.
Everardo M Carneiro1, Marcia Q Latorraca, Eliana Araujo
1Department of Physiology and Biophysic, Institute of Biology, State University of Campinas, Campinas 13083-862, Brasil.
The Journal of Nutritional Biochemistry
|August 19, 2008
Summary
Taurine supplementation improves glucose homeostasis by enhancing insulin secretion and peripheral insulin sensitivity. This study reveals taurine
Area of Science:
- Metabolic research
- Endocrinology
- Amino acid metabolism
Background:
- Taurine is a conditionally essential amino acid involved in glucose homeostasis.
- The precise mechanisms by which taurine influences blood glucose levels remain unclear.
Purpose of the Study:
- To investigate the mechanisms underlying taurine's effects on glucose homeostasis using an animal model.
- To elucidate how taurine supplementation impacts islet cell function, insulin secretion, and peripheral insulin sensitivity.
Main Methods:
- Mice were supplemented with taurine for 30 days.
- Glucose homeostasis was assessed using intraperitoneal glucose tolerance tests (IPGTT).
- Islet cell function, gene expression, insulin signaling, and glucose metabolism were analyzed.
Main Results:
- Taurine-supplemented mice exhibited improved IPGTT results.
- Islets showed increased insulin content, enhanced glucose-stimulated insulin secretion, and altered glucose metabolism.
- Taurine increased the expression of key genes involved in insulin secretion and PDX-1 nuclear translocation.
- Peripheral insulin sensitivity was improved in skeletal muscle and liver tissues.
Conclusions:
- Taurine plays a significant role in controlling glucose homeostasis.
- Taurine regulates glucose homeostasis by modulating gene expression essential for glucose-stimulated insulin secretion.
- Taurine supplementation enhances peripheral insulin sensitivity, contributing to improved glucose control.
Related Concept Videos
01:16Hormones Regulating Blood Glucose
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
01:27Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are co-secreted in...
Insulin and C-peptide are co-secreted in...
01:02Glucose Homeostasis: Regulation of Blood Glucose
Carbohydrates consumed through foods are converted into glucose, a crucial energy source for the body. In the prandial state, high blood glucose levels stimulate the secretion of insulin from the pancreas. Insulin inhibits hepatic glucose production and stimulates glucose uptake and metabolism by muscle and adipose tissue. The excess glucose is converted into glycogen and stored in the liver and muscles.
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
During fasting, when blood glucose levels are low, the pancreas secretes glucagon. it...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.